Idorsia Ltd (SWX:IDIA)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 916.44M +573.5% |
| Revenue (ttm) | 232.51M +213.7% |
| Net Income | -117.94M |
| EPS | -0.59 |
| Shares Out | 250.74M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 396,095 |
| Average Volume | 1,362,375 |
| Open | 3.585 |
| Previous Close | 3.615 |
| Day's Range | 3.580 - 3.750 |
| 52-Week Range | 0.679 - 4.850 |
| Beta | 1.82 |
| RSI | 48.29 |
| Earnings Date | Feb 26, 2026 |
About Idorsia
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company’s product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial t... [Read more]
Financial Performance
In 2024, Idorsia's revenue was 112.51 million, a decrease of -26.17% compared to the previous year's 152.39 million. Losses were -263.76 million, -11.47% less than in 2023.
Financial StatementsNews
Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium
Allschwil, Switzerland – January 30, 2026 Idorsia Ltd (SIX: IDIA) announces that the results of lucerastat treatment over 42-months and the kidney biopsy data will be presented at the 22nd Annual WORL...
Global expansion of Idorsia's QUVIVIQ continues with EMS partnership for Latin America
Ad hoc announcement pursuant to Art. 53 LR Regulatory dossier to obtain marketing authorization for QUVIVIQ has been submitted to ANVISA in Brazil Allschwil, Switzerland – January 28, 2026 Idorsia Ltd...
Idorsia Ltd at JPMorgan Healthcare Conference Transcript
Idorsia Ltd at JPMorgan Healthcare Conference Transcript
Idorsia Ltd (IDRSF) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Idorsia Ltd (IDRSF) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
Idorsia Advances Fabry Disease Program With Encouraging Phase 3 Results
(RTTNews) - Idorsia Ltd (IDIA.SW) announced the publication of pivotal Phase 3 MODIFY study results and its open-label extension (OLE) in Nature Communications. The study evaluated lucerastat, an oral...
Idorsia to present at J.P. Morgan 2026 Healthcare Conference
Allschwil, Switzerland – January 12, 2026 Idorsia Ltd (SIX: IDIA) announces that Srishti Gupta, MD, Chief Executive Officer of Idorsia, will present at the 44th Annual J.P. Morgan Healthcare Conferenc...
Nature Communications reports promising effect of Idorsia's lucerastat on kidney function in Fabry disease
Allschwil, Switzerland – January 12, 2026 Idorsia Ltd (SIX: IDIA) announces the publication of results from the pivotal Phase 3 MODIFY study and its open-label extension (OLE) evaluating lucerastat, a...
Idorsia initiates a proof-of-concept trial with its oral first-in-class selective CCR6 antagonist
Allschwil, Switzerland – January 6, 2026 Idorsia Ltd (SIX: IDIA) announces the initiation of a Phase 2 proof-of-concept trial evaluating IDOR-1117-2520 for participants with moderate-to-severe psorias...
Idorsia's daridorexant in women during menopausal transition age with insomnia
Allschwil, Switzerland – January 5, 2026 Idorsia Ltd (SIX: IDIA) announces the publication of “Efficacy and safety of daridorexant for the treatment of insomnia disorder in women during menopausal tra...
Idorsia's JERAYGO (aprocitentan) approved in Canada for the treatment of resistant hypertension
Idorsia receives approval from Health Canada for JERAYGO ™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension. JERAYGO is a new oral ...
Idorsia's JERAYGO (aprocitentan) approved in Canada for the treatment of resistant hypertension
Allschwil, Switzerland – January 5, 2026 Idorsia Ltd (SIX: IDIA) announces that Health Canada has granted marketing authorization for JERAYGO™ (aprocitentan) for the treatment of resistant hypertensio...
Idorsia Highlights New PRECISION Study Analysis Showing Strong Results For Aprocitentan
(RTTNews) - Idorsia Ltd (IDIA.SW) on Wednesday announced a new analysis from the Phase 3 PRECISION study has been released, showing that aprocitentan can significantly lower blood pressure and reduce ...
New Hypertension publication underscores aprocitentan's potential in managing hypertension patients with CKD
New analysis from landmark Phase 3 PRECISION trial published in Hypertension highlights the renal-protective benefits of aprocitentan in addition to the marked reduction in blood pressure in a high-ri...
Idorsia's treatment for insomnia disorder wins the inaugural Prix Galien Bridges Award in the ‘Best Biotechnology & Pharmaceutical Product' category
Allschwil, Switzerland – December 9, 2025 Idorsia Ltd (SIX: IDIA) announces that its novel treatment for insomnia disorder has been awarded the inaugural Prix Galien Bridges Award in the category of “...
Idorsia's aprocitentan improved key prognostic indicators in patients with difficult-to-control hypertension
New analysis from landmark Phase 3 PRECISION trial published in the Journal of Hypertension highlights aprocitentan led to improvements in dipping pattern and BP load Findings reinforce the role of ap...
Idorsia's aprocitentan improved key prognostic indicators in patients with difficult-to-control hypertension
Allschwil, Switzerland – November 10, 2025 Idorsia Ltd (SIX: IDIA) announced the publication of a new analysis from the landmark Phase 3 PRECISION study in the Journal of Hypertension titled “Effects ...
Idorsia to present new aprocitentan insights at ASN Kidney Week & AHA Scientific Sessions
Allschwil, Switzerland – November 05, 2025 Idorsia Ltd (SIX: IDIA) shares that new analysis of the landmark Phase 3 PRECISION study of aprocitentan, Idorsia's endothelin receptor antagonist, will be p...
QUVIVIQ sales up >130% driving Idorsia toward profitability – 9M 2025 results
Ad hoc announcement pursuant to Art. 53 LR QUVIVIQ (daridorexant) global net sales (excluding sales to partners) increased by >130% year-on-year to CHF 91 million in 9M 2025 – continuing Idorsia's tra...
Idorsia successfully completes an upsized offering of shares – funding the company to overall profitability
Ad hoc announcement pursuant to Art. 53 LR NOT FOR RELEASE, PUBLICATION, DISTRIBUTION IN OR INTO THE UNITED STATES, ITALY, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUB...
Idorsia launches an offering of registered shares – to fund the company to overall profitability
Ad hoc announcement pursuant to Art. 53 LR NOT FOR RELEASE, PUBLICATION, DISTRIBUTION IN OR INTO THE UNITED STATES, ITALY, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUB...
Global expansion of Idorsia's QUVIVIQ continues as Simcere launches in China
Allschwil, Switzerland – September 22, 2025 Idorsia Ltd. (SIX: IDIA) announces that Simcere Pharmaceuticals Group Ltd (2096.HK, “Simcere”) has launched QUVIVIQ ® (daridorexant) in China. QUVIVIQ, Idor...
Idorsia's JERAYGO (aprocitentan) approved in Switzerland for the treatment of resistant hypertension
Idorsia receives approval from Swissmedic for JERAYGO ™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension. JERAYGO is a new oral ant...
Idorsia's JERAYGO (aprocitentan) approved in Switzerland for the treatment of resistant hypertension
Allschwil, Switzerland – September 19, 2025 Idorsia Ltd (SIX: IDIA) announces that Swissmedic has granted marketing authorization for JERAYGO™ (aprocitentan) for the treatment of resistant hypertensio...